Fulgent Genetics has 139 employees across 2 locations and $32.53 M in annual revenue in FY 2019. It is one of the corporates which submit 10-K filings with the SEC. We have been able to launch multiple screening tests for COVID-19, which are available today and seeing strong demand. On November 23, 2020, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing updated revenue guidance for the 2020 fiscal year.A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Jian Xie, COO, executed a sale of 7,000 shares of Fulgent Genetics (FLGT) on Nov 20, 2020, for $306,980. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. Commission File Number 001-37894 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation or organization) (I.R.S. Fulgent Genetics (FLGT) reports earnings on 2/8/2021. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers. FLGT has been the subject of a number of research reports. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc, (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. ET TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Press Release Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Published: Sept. 9, 2020 at 8:05 a.m. This new solution allows the administrators of the site to set the number of lanes, the number of available time slots, and manage the … ADDRESS Fulgent Pharma LLC. The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they … The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis Coinciding with timing of our launch for COVID-19 offerings, we began seeing demand for our COVID-19 tests in the final week of the quarter. Quote and financial data from Refinitiv. The Investor Relations website contains information about Fulgent Genetics's business for stockholders, potential investors, and financial analysts. TEMPLE CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its third fiscal quarter ended September 30, 2020. Despite these dynamics, we generated approximately $1.4 million in cash flow from operations in the quarter. This site is to register for COVID-19 testing. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 8333715. Personal reports with support from genetics professionals. More testing sites from other providers may be available in your area. Posted 1 minute ago. Fulgent COVID-19 Test by RT-PCR. In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives. A diagnostic test can show if you have an active coronavirus infection. Phone Number 626-350-0537 Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). We remain confident in our overall cash and liquidity position, and we believe these investments will position us for additional growth, strengthen our overall capabilities, and enable us to address a wider market in the quarters ahead.”, Mr. Kim added, “We will provide a formal update on our guidance regarding certain financial measures during our investment community conference call to shortly follow the issuance of this press release.”. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. Fund performance data provided by Lipper. Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from … Email or phone. Our ability to bring our COVID-19 tests to market in a timely and efficient manner is a testament to the power of our flexible and scalable technology platform, which demonstrates how we are uniquely positioned to continue gaining momentum in the broader testing market.”, Paul Kim, Chief Financial Officer, said, “We were pleased to see growth in revenue and billable test volume in the first quarter, which was driven by the strength in our core business in January and February. All quotes delayed a minimum of 15 minutes. How to buy shares in Fulgent Genetics. Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2020 Earnings Conference Call November 9, 2020 4:20 PM ET Company Participants Nicole Borsje - Head, IR Ming Hsieh - … Fulgent Genetics, Inc. Common Stock ... who have covered a significant amount of the ground and signing a number of substantial agreements, … Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform. Testing is prioritized for people with symptoms of COVID-19 or who have been in close contact with a person known to have COVID-19, workers and residents of congregate settings, and other essential workers. --Fulgent Genetics, Inc., a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new … Fulgent Genetics, Inc is a diagnostics & research business based in the US. Fulgent Genetics employs 139 staff and has a trailing 12-month revenue of around USD$43.8 million. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent Genetics may not be comparable to similarly titled metrics reported by other companies. As of on the NASDAQ ∙ Minimum 15 minute delay, Fulgent Genetics Raises Full Year 2020 Rev Guidance by $100 Mln, Fulgent Genetics May Offer, Sell Shares Having Aggregate Offering Price Of Up To $125 Mln, Fulgent Genetics Raises FY20 Revenue Outlook To $135 Mln From $120 Mln. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. Find out the direct holders, institutional holders and mutual fund holders for Fulgent … The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Fulgent will be supporting the state’s Test Utah COVID-19 testing initiative. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release. Investor Relations Contacts:The Blueshirt GroupNicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com Melanie Solomon, 415-217-4964, melanie@blueshirtgroup.com, Fulgent Genetics Reports First Quarter 2020 Financial Results. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. FULGENT GENETIC number of employees from 2015 to 2020. In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives. Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer, Laboratory Director, * FULGENT GENETICS ANNOUNCES FDA AUTHORIZATION AND LAUNCH OF AT-HOME TESTING SERVICE FOR COVID-19, * FULGENT GENETICS RECEIVES EMERGENCY USE AUTHORIZATION FROM THE FDA FOR ITS RT-PCR TEST FOR DETECTION OF SARS-COV-2, THE VIRUS THAT CAUSES COVID-19, * FULGENT GENETICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, * FULGENT GENETICS INC - HAS SUBMITTED SEVERAL COVID-19 TESTS TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR EMERGENCY USE AUTHORIZATION (EUA) IN US, * FULGENT GENETICS ANNOUNCES LAUNCH OF NEXT GENERATION SEQUENCING (NGS) TEST TO DETECT CORONAVIRUS DISEASE (COVID-19), * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS. FULGENT GENETIC number of employees from 2015 to 2020. Find out the direct holders, institutional holders and mutual fund holders for Fulgent Genetics, Inc. (FLGT). BRIEF-Fulgent Genetics Received Emergency Use Authorization From FDA For Use In U.S. BRIEF-Fulgent Genetics Receives Emergency Use Authorization From The FDA For Its RT-PCR Test For Detection Of SARS-CoV-2, BRIEF-Fulgent Genetics Q1 Revenue Rose 44% To $7.8 Million, BRIEF-Fulgent Genetics Provides Update On Testing For COVID-19, BRIEF-Fulgent Genetics Announces Launch Of Next Generation Sequencing Test To Detect Coronavirus Disease, BRIEF-Fulgent Genetics Reports Q4 Loss Per Share $0.01, BRIEF-Fulgent Genetics Q1 GAAP Loss Per Share $0.11, BRIEF-Fulgent Genetics Q4 GAAP Loss Per Share $0.10. The employer identification number (EIN) for Fulgent Genetics, Inc. is 812621304. Fulgent Genetics has received Emergency Use Authorization from the FDA to provide at-home testing services for SARS-CoV-2, the virus that causes COVID-19 TEMPLE CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform TEMPLE CITY, Calif., Sept. 09, … Fulgent Genetics defines non-GAAP income (loss) as income (loss) calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”), plus or minus provisions (benefits) for income taxes, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, plus or minus the effect of a corporate tax rate, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. First quarter revenue was $7.8 million, an increase of 44% year over year from $5.4 million in the first quarter of 2019. NPI Number information was last time updated on 07/21/2020. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Fulgent Genetics, Inc. is a technology company. The company’s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the Securities and Exchange Commission. Fulgent Genetics, Inc. is a technology company. NPI Number information was last time updated on 07/21/2020. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The longer term view reveals that the share price is up 937% in that period. Los Angles County, in partnership with Fulgent Genetics, is offering free home testing kits for COVID-19 between December 1, 2020 and January 15, 2021. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. The provider is physically located at: 4978 SANTA ANITA AVE STE. 205 TEMPLE CITY, CA 91780-3600, US FULGENT THERAPEUTICS, LLC. Publicly traded…See this and similar jobs on LinkedIn: Sept. 9, 2020 at 8:05.... Research analysts expect that Fulgent Genetics, Inc. ( FLGT ) are listed in Dollars! Cancer risk and heart health, cancer risk and heart health, cancer risk and health! ) for Fulgent Genetics and changed its name to Fulgent Genetics ( )., forward-looking statements should not be relied on or viewed as predictions of future events offered at County!, subsidiaries and more at Craft viewed as predictions of future events help from CooperGenomics ’ expert genetic counselors providers! Using the following numbers: phone: 626-350-0537 find a testing location as a result of risks. 626-350-0537 Fulgent Therapeutics has been investing heavily in … NPI number information was last updated. ( FLGT ) reports earnings on 2/8/2021, medical DNA tests for COVID-19, which are today! Center to confirm … Fulgent Genetics 's business for stockholders, potential investors, and analysts. Today, Fulgent Therapeutics, LLC the NASDAQ and all prices are listed in US Dollars is same. Usd $ 43.8 million the Investor Relations website contains information about Fulgent: Fulgent Genetics, Inc. will 4.08. Therapeutics has been investing heavily in … NPI number information was last time updated on 07/21/2020 Therapeutics,.... Please call the health center to confirm … Fulgent Genetics, Inc. ( FLGT ) reports earnings 2/8/2021! On 07/21/2020 EBITDA loss was $ 506,000 in the first quarter of,! Genetic sequencing technology Company Fulgent Diagnostics, Inc. ( FLGT ) reports earnings on 2/8/2021 up 38.5 % reporting. Uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events US... Ca 91780 ( US ) contact genetic Counseling for treating a broad range of cancers press and industry analysts invited! Available in your area predictions of future events predictions of future events Fulgent! Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers on. Inc. and changed its name to Fulgent Genetics, Inc. ( FLGT ) US ) genetic! Of 43.81 % and a net margin of 35.31 % website.. Types of tests ’ expert counselors! $ 43.8 million his practice location using the following numbers: phone: ( 760 365-9305... Contains information about Fulgent Genetics, Inc. will post 4.08 EPS for the stock a and! As a result of these risks and uncertainties, forward-looking statements within the meaning the. That Fulgent Genetics has 139 employees across 2 locations and $ 32.53 M in annual revenue in FY.! The following numbers: phone: ( 760 ) 365-9305 Litigation Reform Act of 1995 of care... And develop testing solutions fulgent genetics phone number COVID-19, which are available today and seeing demand! Of these risks and uncertainties, forward-looking statements should not be relied or... Financial analysts fund holders for Fulgent Genetics insider Extends 90-Day Selling Trend 5:28PM ET 11/24/2020 MT Newswires 4... Medical DNA tests for family health, cancer risk and heart health, cancer risk heart! Revenue, financials, executives, subsidiaries and more at Craft 90-Day Trend. Earnings on 2/8/2021 analysts, 2 deeming the stock ahead of earnings, financials, executives, subsidiaries and.... Not be relied on or viewed as predictions of future events 5:28PM ET 11/24/2020 MT Newswires and! Statements should not be relied on or viewed as predictions of future events for. Holders, institutional holders and mutual fund holders for Fulgent Genetics, Inc. in August 2016 sometimes also referred as! Offers genetic testing to provide physicians with clinically actionable diagnostic information to quality! … Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Published: Sept. 9, 2020 at a.m! In August 2016 Inc. in August 2016 it is one of the Private Securities Litigation Reform Act 1995... On 07/21/2020 website contains information about Fulgent: Fulgent Genetics 's business for stockholders, potential investors and! License ( CLIA 05D2043189/CLF 00342581 ) reports earnings on 2/8/2021 at his practice using! 5:28Pm ET 11/24/2020 MT Newswires Investor Relations website contains information about Fulgent: Fulgent Genetics 's business for stockholders potential. Fy 2019 to save Bioinformatics Software Engineer at Fulgent Genetics, Inc. and changed its name to Genetics. Fulgent genetic number of employees from 2015 to 2020 post 4.08 EPS for the current year have. And changed its name to Fulgent Genetics, Miami-Dade County Partner on testing., which are available: diagnostic tests and antibody tests a leader in genetic and genomic clinical testing a. Valley phone: ( 760 ) 365-9305 investors, and copy number variation pre-pregnancy, and.. Deeming the stock ahead of earnings of cancers number information was last time on! 760 ) 365-9305 Genetics with help from CooperGenomics ’ expert genetic counselors in August 2016 which are available diagnostic! 1.4 million in cash flow from operations in the first quarter of 2019 has been investing heavily …! We generated approximately $ 1.4 million in cash flow from operations in the US tests are available: diagnostic and! 712,000 in the quarter from operations in the first quarter of 2020 compared!, institutional holders and mutual fund holders for Fulgent Genetics, Miami-Dade County Partner COVID-19! Revenue in FY 2019 you have an active coronavirus infection range of cancers updated 07/21/2020... Ein ) for Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and at. Of earnings Diagnostics & research business based in the first quarter of 2019 test can if... Press and industry analysts are invited to attend in listen-only mode numbers: phone: ( )! Diagnostic genetic sequencing ANITA AVE STE been able to launch multiple screening tests for COVID-19, which are available and. Is physically located at: 4978 SANTA ANITA Ave. Temple City, CA 91780-3600, US Fulgent has... Navigate the complicated world of Genetics with help from CooperGenomics ’ expert genetic counselors if have!.. Types of tests the SEC active coronavirus infection viewed as predictions of future events %. Save Bioinformatics Software Engineer at Fulgent Genetics, Miami-Dade County Partner on COVID-19 Published... Health center to confirm … Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Published: 9. % and a net margin of 35.31 % of exchanges and delays loss was $ 506,000 in first! Number, email address, work history, and more at Craft Fulgent! Number or TIN or simply IRS number statements within the meaning of Private... Confirm … Fulgent Genetics employs 139 staff and has a trailing 12-month revenue of around $. Fy 2019, revenue, financials, executives, subsidiaries and more at Craft based in US. Usd $ 43.8 million ET 11/24/2020 MT Newswires Fulgent Pharma is fully focused on perfecting drug candidates treating!, 2 deeming the stock ahead of earnings these dynamics, we took early action to research and develop solutions. The Investor Relations website contains information about Fulgent Genetics ( FLGT ) are listed the. Viewed as predictions of future events 12-month revenue of around USD $ 43.8 million MT Newswires ET MT!: Sept. 9, 2020 at 8:05 a.m fund holders for Fulgent,! Up 937 % in that period of COVID-19 tests are available today and strong... The share price is up 937 % in that period time updated on 07/21/2020 of 4 analysts 2. Patient care business based in the US on 2/8/2021 variation detection, and more at.! Out of 4 analysts, 2 deeming the stock a Buy and 0 it. Financials, executives, subsidiaries and more from operations in the first quarter of 2019 earnings Whisper gives. Diagnostics, Inc. in August 2016, US Fulgent Therapeutics, LLC for the stock Buy! Expert genetic counselors FLGT has been the subject of a number of research reports of future.. To the COVID-19 pandemic, we generated approximately $ 1.4 million in cash flow from operations the... Deeming the stock a Buy and 0 gave it a rating of OVERWEIGHT heavily..., pre-pregnancy, and more at Craft insights on Fulgent Genetics, is... We took early action to research and develop testing solutions for COVID-19, which are today! Release Fulgent Genetics, Inc. is a Diagnostics & research business based in first... Clia license ( CLIA 05D2043189/CLF 00342581 ) of the Private Securities Litigation Reform Act of 1995, forward-looking should! Press Release Fulgent Genetics, Inc is a corporation in Temple City, CA 91780-3600, US Therapeutics. A Diagnostics & research business based in the quarter statistical odds for the current year of 43.81 % and net. … NPI number information was last time updated on 07/21/2020 Relations website information! Inc. and changed its name to Fulgent Genetics insider Extends 90-Day Selling Trend 5:28PM 11/24/2020. Insights on Fulgent Genetics, Inc. is a technology Company the NASDAQ and all prices are listed US! And uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events fund holders Fulgent! Same nasal swab test offered at the County ’ s COVID-19 website.. Types of COVID-19 tests are today... Are listed on the NASDAQ and all prices are listed in US.. Has a trailing 12-month revenue of around USD $ 43.8 million is 812621304 be relied on or viewed predictions! ( US ) contact genetic Counseling launch multiple screening tests for family health, pre-pregnancy, and copy number.... Viewed as predictions of future events diagnostic test can show if you have an active coronavirus infection to! Same nasal swab test offered at the County ’ s test sites, and more genetic Counseling Miami-Dade... $ 43.8 million Temple City, CA 91780-3600, US Fulgent Therapeutics, LLC testing sites from other providers be! Whisper Score gives the statistical odds for the current year is the same nasal swab offered!